vs
Apellis Pharmaceuticals, Inc.（APLS）与UNIFI INC（UFI）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是UNIFI INC的1.6倍（$199.9M vs $121.4M），UNIFI INC净利率更高（-8.0% vs -29.5%，领先21.5%），Apellis Pharmaceuticals, Inc.同比增速更快（-5.9% vs -12.6%），UNIFI INC自由现金流更多（$24.2M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -9.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
优尼飞航空是北美规模最大的航空地勤服务供应商。公司成立于2018年末，达美航空将旗下子公司DAL环球服务的部分股权出售给阿根布莱特控股后，双方合资组建了该企业，目前阿根布莱特持有公司51%股份，达美航空持有49%股份。
APLS vs UFI — 直观对比
营收规模更大
APLS
是对方的1.6倍
$121.4M
营收增速更快
APLS
高出6.7%
-12.6%
净利率更高
UFI
高出21.5%
-29.5%
自由现金流更多
UFI
多$38.5M
$-14.3M
两年增速更快
APLS
近两年复合增速
-9.7%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $121.4M |
| 净利润 | $-59.0M | $-9.7M |
| 毛利率 | — | 3.0% |
| 营业利润率 | -25.6% | -6.0% |
| 净利率 | -29.5% | -8.0% |
| 营收同比 | -5.9% | -12.6% |
| 净利润同比 | -62.2% | 14.8% |
| 每股收益（稀释后） | $-0.40 | $-0.53 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSUFI
| Q4 25 | $199.9M | $121.4M | ||
| Q3 25 | $458.6M | $135.7M | ||
| Q2 25 | $178.5M | $138.5M | ||
| Q1 25 | $166.8M | $146.6M | ||
| Q4 24 | $212.5M | $138.9M | ||
| Q3 24 | $196.8M | $147.4M | ||
| Q2 24 | $199.7M | $157.5M | ||
| Q1 24 | $172.3M | $149.0M |
净利润APLSUFI
| Q4 25 | $-59.0M | $-9.7M | ||
| Q3 25 | $215.7M | $-11.4M | ||
| Q2 25 | $-42.2M | $15.5M | ||
| Q1 25 | $-92.2M | $-16.8M | ||
| Q4 24 | $-36.4M | $-11.4M | ||
| Q3 24 | $-57.4M | $-7.6M | ||
| Q2 24 | $-37.7M | $-4.0M | ||
| Q1 24 | $-66.4M | $-10.3M |
毛利率APLSUFI
| Q4 25 | — | 3.0% | ||
| Q3 25 | — | 2.5% | ||
| Q2 25 | — | -0.8% | ||
| Q1 25 | — | -0.3% | ||
| Q4 24 | — | 0.4% | ||
| Q3 24 | — | 6.4% | ||
| Q2 24 | — | 6.9% | ||
| Q1 24 | — | 3.2% |
营业利润率APLSUFI
| Q4 25 | -25.6% | -6.0% | ||
| Q3 25 | 48.7% | -7.1% | ||
| Q2 25 | -18.6% | 10.9% | ||
| Q1 25 | -50.0% | -9.5% | ||
| Q4 24 | -12.3% | -5.4% | ||
| Q3 24 | -24.0% | -2.2% | ||
| Q2 24 | -14.7% | -0.5% | ||
| Q1 24 | -36.0% | -4.6% |
净利率APLSUFI
| Q4 25 | -29.5% | -8.0% | ||
| Q3 25 | 47.0% | -8.4% | ||
| Q2 25 | -23.6% | 11.2% | ||
| Q1 25 | -55.3% | -11.5% | ||
| Q4 24 | -17.1% | -8.2% | ||
| Q3 24 | -29.2% | -5.2% | ||
| Q2 24 | -18.9% | -2.5% | ||
| Q1 24 | -38.5% | -6.9% |
每股收益（稀释后）APLSUFI
| Q4 25 | $-0.40 | $-0.53 | ||
| Q3 25 | $1.67 | $-0.62 | ||
| Q2 25 | $-0.33 | $0.85 | ||
| Q1 25 | $-0.74 | $-0.92 | ||
| Q4 24 | $-0.30 | $-0.62 | ||
| Q3 24 | $-0.46 | $-0.42 | ||
| Q2 24 | $-0.30 | $-0.21 | ||
| Q1 24 | $-0.54 | $-0.57 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $30.2M |
| 总债务越低越好 | — | $92.6M |
| 股东权益账面价值 | $370.1M | $230.0M |
| 总资产 | $1.1B | $382.9M |
| 负债/权益比越低杠杆越低 | — | 0.40× |
8季度趋势，按日历期对齐
现金及短期投资APLSUFI
| Q4 25 | $466.2M | $30.2M | ||
| Q3 25 | $479.2M | $20.6M | ||
| Q2 25 | $370.0M | $22.7M | ||
| Q1 25 | $358.4M | $16.3M | ||
| Q4 24 | $411.3M | $18.7M | ||
| Q3 24 | $396.9M | $13.7M | ||
| Q2 24 | $360.1M | $26.8M | ||
| Q1 24 | $325.9M | $27.7M |
总债务APLSUFI
| Q4 25 | — | $92.6M | ||
| Q3 25 | — | $107.5M | ||
| Q2 25 | — | $95.7M | ||
| Q1 25 | — | $127.9M | ||
| Q4 24 | — | $123.0M | ||
| Q3 24 | — | $119.3M | ||
| Q2 24 | — | $117.8M | ||
| Q1 24 | $93.1M | $116.1M |
股东权益APLSUFI
| Q4 25 | $370.1M | $230.0M | ||
| Q3 25 | $401.2M | $241.1M | ||
| Q2 25 | $156.3M | $249.5M | ||
| Q1 25 | $164.2M | $228.4M | ||
| Q4 24 | $228.5M | $237.2M | ||
| Q3 24 | $237.1M | $259.7M | ||
| Q2 24 | $264.3M | $263.4M | ||
| Q1 24 | $266.7M | $277.8M |
总资产APLSUFI
| Q4 25 | $1.1B | $382.9M | ||
| Q3 25 | $1.1B | $424.6M | ||
| Q2 25 | $821.4M | $426.9M | ||
| Q1 25 | $807.3M | $446.5M | ||
| Q4 24 | $885.1M | $439.7M | ||
| Q3 24 | $901.9M | $467.0M | ||
| Q2 24 | $904.5M | $469.2M | ||
| Q1 24 | $831.9M | $482.6M |
负债/权益比APLSUFI
| Q4 25 | — | 0.40× | ||
| Q3 25 | — | 0.45× | ||
| Q2 25 | — | 0.38× | ||
| Q1 25 | — | 0.56× | ||
| Q4 24 | — | 0.52× | ||
| Q3 24 | — | 0.46× | ||
| Q2 24 | — | 0.45× | ||
| Q1 24 | 0.35× | 0.42× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $25.3M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $24.2M |
| 自由现金流率自由现金流/营收 | -7.1% | 20.0% |
| 资本支出强度资本支出/营收 | 0.1% | 0.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $1.4M |
8季度趋势，按日历期对齐
经营现金流APLSUFI
| Q4 25 | $-14.2M | $25.3M | ||
| Q3 25 | $108.5M | $-8.9M | ||
| Q2 25 | $4.4M | $-1.3M | ||
| Q1 25 | $-53.4M | $-5.0M | ||
| Q4 24 | $19.4M | $-2.2M | ||
| Q3 24 | $34.1M | $-12.8M | ||
| Q2 24 | $-8.3M | $932.0K | ||
| Q1 24 | $-133.0M | $-1.4M |
自由现金流APLSUFI
| Q4 25 | $-14.3M | $24.2M | ||
| Q3 25 | $108.3M | $-10.9M | ||
| Q2 25 | $4.4M | $-3.9M | ||
| Q1 25 | $-53.4M | $-8.0M | ||
| Q4 24 | $19.3M | $-5.1M | ||
| Q3 24 | — | $-14.9M | ||
| Q2 24 | $-8.4M | $-1.7M | ||
| Q1 24 | $-133.3M | $-3.9M |
自由现金流率APLSUFI
| Q4 25 | -7.1% | 20.0% | ||
| Q3 25 | 23.6% | -8.1% | ||
| Q2 25 | 2.5% | -2.8% | ||
| Q1 25 | -32.0% | -5.4% | ||
| Q4 24 | 9.1% | -3.7% | ||
| Q3 24 | — | -10.1% | ||
| Q2 24 | -4.2% | -1.1% | ||
| Q1 24 | -77.3% | -2.6% |
资本支出强度APLSUFI
| Q4 25 | 0.1% | 0.9% | ||
| Q3 25 | 0.0% | 1.5% | ||
| Q2 25 | 0.0% | 1.9% | ||
| Q1 25 | 0.0% | 2.0% | ||
| Q4 24 | 0.0% | 2.1% | ||
| Q3 24 | 0.0% | 1.4% | ||
| Q2 24 | 0.0% | 1.7% | ||
| Q1 24 | 0.2% | 1.7% |
现金转化率APLSUFI
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | -0.09× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
UFI
| Other | $67.8M | 56% |
| REPREVE Fiber | $34.3M | 28% |
| Export Sales From US Operations | $10.5M | 9% |
| All Other Foreign Countries | $8.8M | 7% |
